This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 1, 2009
Last updated: April 5, 2010
Last verified: April 2010
The aims of the study are to assess the safety, tolerability and pharmacokinetics of ER tablets of AZD3241 following multiple ascending doses administered to healthy male and female subjects including the effect of food.

Condition Intervention Phase
Healthy Drug: AZD3241 Drug: Placebo Tablet Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety variables (adverse events, vital signs, ECG, safety lab) [ Time Frame: Assessments performed at frequent timepoints during a 4-8 week period ]

Secondary Outcome Measures:
  • To characterize the pharmacokinetics of AZD3241 in plasma [ Time Frame: Frequent sampling occasions during some study days for a 4-8 weeks period ]

Enrollment: 77
Study Start Date: June 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZD3241
AZD3241 Tablets
Drug: AZD3241
Oral Tablet, Repeated Administration
Experimental: Placebo
Placebo Tablets
Drug: Placebo Tablet
Oral Tablet. Repeated Administration


Ages Eligible for Study:   30 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and female subjects 30-65 years
  • Body Mass Index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg

Exclusion Criteria:

  • History of any clinically significant disease or disorder
  • History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
  • Previous history of frequent pre-syncope or syncope
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00914303

Research Site
Uppsala, Sweden
Sponsors and Collaborators
Study Director: Rolf Karlsten, MD Medical Science Director AstraZeneca R&D Södertälje.
Principal Investigator: Wolfgang Kuhn, MD, PhD Quintiles AB Phase I Unit, Uppsala, Sweden
  More Information

Responsible Party: Rolf Karlsten , MD, PhD, Medical Science Director, AstraZeneca Pharmaceuticals Identifier: NCT00914303     History of Changes
Other Study ID Numbers: D0490C00002
EudraCT No 2007-003145-33
Study First Received: June 1, 2009
Last Updated: April 5, 2010

Keywords provided by AstraZeneca:
Healthy volunteer study processed this record on July 28, 2017